The comparison of nasal irrigation outcome between 3% NaCl and 0.9% NaCl in adults majority with intermittent allergic rhinitis: A randomized double-blind study

Kedsaraporn Yata, Chonticha Srivanitchapoom

Abstract

Background: Management of allergic rhinitis with oral antihistamine and steroid nasal spray are the standard treatment which is recommended by Allergic Rhinitis and its Impact on Asthma guidelines. In addition, nasal irrigation as an adjuvant therapy also provides a satisfactory result.

Objective: To compare the treatment outcome in adults majority with intermittent allergic rhinitis who receive different concentrations of nasal irrigation.

Methods: The prospective randomized double-blind study was performed in 80 patients. All patients were prescribed oral antihistamine and nasal irrigated solution between 3% NaCl and 0.9% NaCl. Nasal congestion and rhinorrhea were evaluated at baseline, first and second weeks after treatment. Assessments were measured by nasal congestion visual analog scale rhinorrhea visual analog scale, inferior turbinate size, and peak nasal expiratory flow rate (PNEFR). A p value of < 0.05 was considered statistically significant.

Results: There were 40 patients in each group of the study. Patients reported satisfactory experience after using saline irrigation at first and second weeks in both solutions (p value < 0.001). However, when compared between groups, no significant differences for all parameters were reported. PNEFR showed good results after the first week of 3% NaCl irrigation (p value = 0.001), while 0.9% NaCl had good results after the second week (p value < 0.001).

Conclusion: Both add-on treatments have a significant improvement of all 4 parameters assessed in the study: nasal congestion, rhinorrhea, inferior turbinate size and PNEFR. Of note, 3% NaCl but not 0.9 NaCl had improved the PNEFR earlier from 1 week of the treatment.

Key words: nasal irrigation, 3% NaCl, 0.9% NaCl, hypertonic saline, allergic rhinitis

Introduction

Allergic rhinitis is a chronic disease which affects 25-35% of the worldwide population. Thailand has a disease incidence of approximately 10-45%. The common presenting symptoms which usually negatively impact patient's quality of life include nasal obstruction, rhinorrhea, nasal itching, and sneezing. According to Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, allergen avoidance, oral antihistamines, and topical nasal steroid spray are the standard treatment modalities for allergic patients. However, some patients do not achieve a good outcome even they follow the guidelines. Additionally, allergen avoidance is unrealistic in some environments. Therefore, further medications, such as pseudoephedrine or phenylephrine, are prescribed to relieve the allergic symptoms. However, those drugs have side effects and may interact with other medications the patient is taking.

Nasal irrigation is an adjuvant therapy that minimizes the problems of allergen avoidance and additional drug usage. The mechanisms of the nasal procedure are to wash out
discharge, inflammatory substances, and allergens in the nasal cavity. In addition, some studies mentioned in the advantage of hypertonicity solution by decreases nasal edema and improve of nasal mucociliary clearance through the fluid secretion that may associated with upregulation of chloride channel. However, there is no definite recommendation for specific concentration in saline solution.

The aim of this study was to compare symptoms of nasal congestion and rhinorrhea in adults majority with intermittent allergic rhinitis patients who receive add-on treatment with hypertonic and isotonic nasal saline solution and to provide evidence for health-care practitioners in the selection of an appropriate saline irrigated solution.

Methods

The prospective randomized controlled trial double-blind, paralleled, study was conducted at the otolaryngology unit and was reported in the line with the CONSORT guidelines. The protocol of the investigation was approved by the Institutional Review Board. The clinical trial registration number was TCTR20200430003. The study was conducted between July 2018 and June 2019. The study focused on adult allergic rhinitis patients who were diagnosed according to ARIA classification. Inclusion criteria were: 1) age ≥ 15 years old; 2) presence of active symptoms of allergic rhinitis more than 1 week; 3) no history of nasal irrigation or steroid nasal spray used at least 1 month before entry the study; and 4) no symptoms/signs of active upper respiratory tract infection by bacteria or virus. Fever (BT > 37.5°C), discoloring of nasal discharge, cough, facial pain, otalgia, sore throat, and cervical lymphadenopathy were defined as an active infection. Patients who presented with nasal anatomical variation, such as deviated nasal septum, sinonasal polyp and/or neoplasm, prior history of nose and sinus surgery, chronic lung disease, smoking, seeking further medical treatment and used concomitant drugs out of the trial during the study were excluded.

Participants and Blinding

All participants were provided detailed information about the study by the researcher and completed the written informed consent. Patient demographic data included age, sex, body mass index (BMI), duration of symptoms, and ARIA classification. Each patient was prescribed only oral antihistamine (loratadine (10 mg)) one tablet before bed-time and improve of nasal mucociliary clearance through the fluid secretion that may associated with upregulation of chloride channel. However, there is no definite recommendation for specific concentration in saline solution.

The primary outcome in this study was nasal congestion, which was evaluated by subjective and objective assessment, while the secondary outcome of rhinorrhea was assessed only by subjective method. Measurement was performed at 3 points of time: baseline, at the end of the first week, and at the second week of nasal irrigation. Last nasal irrigation before testing was performed in the evening of the day before each visit. Visual analog scale (VAS) which offers ease of response, has a precise scaling of 0 to 10 and more specific to each nasal symptom was selected to be a subjective measurement. Nasal congestion visual analog scale (NCVAS) and rhinorrhea visual analog scale (RVAS) were used for obstruction and rhinorrhea assessment. Objective assessment can provide more accurate results than the subjective method. This study had 1 objective module which was peak nasal expiratory flow rate (PNEFR). PNEFR was the volume of expiratory flow, which was reported as liters per minute (L/min) in exact value. PNEFR was measured using a peak flow meter with anesthetic mask. Patients were asked to sit in the testing room for 30 minutes before testing to familiarize them with the atmosphere. The fitted anesthetic mask was applied to the nose. Then, the patient was asked to take a deep inspiration into the mouth, close the mouth, and breathe out forcefully through the nose. The test was repeated 3 times, and the best value was selected as the PNEFR result. The size of inferior turbinate which referred to total nasal space was modified from the study of Camacho et al. Turbinate was grading from I-IV by anterior rhinoscopy assessment, grade I was 0-25% of total airway space, grade II was 26-50% of total airway space, grade III was 51-75% of total airway space, and grade IV was 76-100% of total airway space. This study modified grading to scoring as 1 to 4 points, respectively: grade I for 1 point, grade II for 2 points, grade III for 3 points, and grade IV for 4 points. In addition, inferior turbinate size (ITS) was measured via flexible nasal endoscopy, and it was regarded as a subjective measurement.
Statistical analysis

Statistical methods were calculated using IBM SPSS Statistics for Windows, version 20 (IBM Crop). All continuous data were presented as mean; independent t-test and paired t-test were used to compare between group and same group means, respectively. However, for nonparametric variable, the statistical analysis was calculated by using Mann Whitney U test to compare difference between two groups median and Wilcoxon signed rank test to compare two related samples median. All categorical data were reported in percentage. Clinical data and disease variables were analyzed and compared between groups by calculating the odds ratio (OR) and 95% confidence interval (CI) univariate regression analyses to assess the significant difference. The chi-squared test and Fisher’s exact test were used for the comparison. P-values less than 0.05 were considered significant.

Results

Eighty patients were eligible for this study. Patients were randomized in to 2 groups equally. Intervention with 3% and 0.9% NaCl saline irrigation was assigned for each group. Subjective and objective outcome assessments were measured to identify the nasal congestion and rhinorrhea symptoms which were the outcome of this study. Baseline 1 and 2 weeks after starting the nasal irrigation measurement were performed in all patients with no drop out of participants. CONSORT flow chart is shown in Figure 1. Female sex was predominant, making up 63 cases (78.7%). Average age was 44.9 years old. The majority of patients present with normal range of BMI (68.7%). According to ARIA classification, 67.5% of participants were classified as mild intermittent, followed by 30% who were classified as moderate to severe intermittent, and only 2.5% were classified as having mild persistent symptoms. The average duration of symptoms was 5.4 years.

Baseline demographic data and clinical characteristic of each group are described in Table 1, which showed no statistical significance. The subjective scale before irrigation started was quite similar in both groups, with 8 of NCV AS, 8 of RV AS, and 3 of ITS. The objective assessed was also similar, with PNEFR reported as 60 L/min. At first week after using saline irrigation, patients reported satisfactory outcomes in both concentrations. (Table 2) Rhinorrhea evaluated by RVAS was personally minimized (p value < 0.001), while nasal congestion also improved by subjective (NCVAS) and (ITS) measurement (p value < 0.001). Furthermore, PNEFR showed good results only in 3% NaCl irrigation (p value = 0.001). Second week evaluation demonstrated improvement of all assessment parameters in both hypertonic and isotonic solutions. (Table 3) However, when compared between groups for each parameter in the same period of times, no significant difference for all parameters were reported. (Table 4)

Two cases (5%) in the hypertonic saline noticed nasal discomfort (light pain sensation) after irrigation at first time but their spontaneous recovery. All patients tolerated nasal saline irrigation well. No adverse effects that interrupted the study was reported.

![Figure 1. CONSORT flow diagram.](image-url)
### Table 1. Patient demographic data

| Variable                      | 3% NaCl       | 0.9% NaCl       | p value       | OR, 95% CI       |
|-------------------------------|---------------|-----------------|---------------|-----------------|
| Sex                           |               |                 |               |                 |
| Male                          | 9 (22.5)      | 8 (20)          | 0.900         | 0.969, (0.397-3.395) |
| Female                        | 31 (77.5)     | 32 (80)         |               |                 |
| Age (y) median (IQR)          | 43 (25.75)    | 43 (25.50)      | 0.634*        | -               |
| BMI                           |               |                 |               |                 |
| Abnormal                      | 15 (37.5)     | 10 (25)         | 0.230         | 0.556, (0.213-1.451) |
| Normal                        | 25 (62.5)     | 30 (75)         |               |                 |
| Duration of symptoms (y) median (IQR) | 3 (7.25)      | 2.50 (6.75)    | 0.833*        | -               |
| ARIA classification           |               |                 |               |                 |
| Mild intermittent             | 27 (67.5)     | 27 (67.5)       | 0.734         | 0.846, (0.323-2.219) |
| Moderate-severe intermittent  | 11 (27.5)     | 13 (32.5)       |               |                 |
| Mild persistent               | 2 (5)         |                 |               |                 |
| Moderate-severe persistent    |               |                 |               |                 |

IQR = interquartile range, BMI = body mass index, ARIA = Allergic Rhinitis and its Impact on Asthma

(*) Mann Whitney U test

(**) The patients received only oral antihistamine (without intranasal steroid spray)

### Table 2. The comparison of outcome assessment at baseline and first week after saline nasal irrigation

| Outcome assessment | Saline solution | Baseline | First week | p value       |
|--------------------|-----------------|----------|------------|---------------|
| NCVAS; median (IQR) | 3% NaCl         | 8 (2.50) | 6 (3.00)   | < 0.001**     |
|                    | 0.9% NaCl       | 8 (2.75) | 5.50 (3.00) | < 0.001**     |
| RVAS; median (IQR) | 3% NaCl         | 8 (2.75) | 6 (2.75)   | < 0.001**     |
|                    | 0.9% NaCl       | 8 (1.00) | 5.50 (3.00) | < 0.001**     |
| ITS; median (IQR)  | 3% NaCl         | 3 (0.00) | 2 (1.00)   | < 0.001**     |
|                    | 0.9% NaCl       | 3 (1.00) | 2 (1.00)   | < 0.001**     |
| PNEFR (L/min); median (IQR) | 3% NaCl | 60 (27.50) | 70 (28.75) | 0.001** |
|                    | 0.9% NaCl       | 60 (20.00) | 65 (25.00) | 0.083** |

NCVAS = nasal congestion visual analog scale, IQR = interquartile range, RVAS = rhinorrhea visual analog scale, ITS = inferior turbinate size, PNEFR = peak nasal expiratory flow rate

(**) Wilcoxon signed rank test

### Table 3. The comparison of outcome assessment at baseline and second week after saline nasal irrigation

| Outcome assessment | Saline solution | Baseline | Second week | p value       |
|--------------------|-----------------|----------|-------------|---------------|
| NCVAS; median (IQR) | 3% NaCl         | 8 (2.50) | 4 (2.00)    | < 0.001**     |
|                    | 0.9% NaCl       | 8 (2.75) | 4 (2.00)    | < 0.001**     |
| RVAS; median (IQR) | 3% NaCl         | 8 (2.75) | 4 (2.00)    | < 0.001**     |
|                    | 0.9% NaCl       | 8 (1.00) | 4 (3.00)    | < 0.001**     |
| ITS; median (IQR)  | 3% NaCl         | 3 (0.00) | 1 (1.00)    | < 0.001**     |
|                    | 0.9% NaCl       | 3 (1.00) | 1 (1.00)    | < 0.001**     |
| PNEFR (L/min); median (IQR) | 3% NaCl | 60 (27.50) | 75 (25.00) | < 0.001** |
|                    | 0.9% NaCl       | 60 (20.00) | 75 (30.00) | < 0.001** |

NCVAS = nasal congestion visual analog scale, IQR = interquartile range, RVAS = rhinorrhea visual analog scale, ITS = inferior turbinate size, PNEFR = peak nasal expiratory flow rate

(**) Wilcoxon signed rank test

### Table 4. Outcome assessment between 3% NaCl and 0.9% NaCl nasal irrigation at baseline, 1 week, and 2 weeks after starting the irrigation in the same period of time

| Outcome assessment | 3% NaCl | 0.9% NaCl | p value       |
|--------------------|---------|----------|---------------|
| NCVAS; median (IQR) | 3% NaCl | 8 (2.50) | 8 (2.75) | 0.854* |
|                    | 0.9% NaCl | 8 (2.75) | 5.50 (3.00) | 0.440* |
| 1 week             | 6 (3.00) | 5.50 (3.00) | 0.918* |
| 2 weeks            | 4 (2.00) | 4 (3.00) | 0.304* |
| RVAS; median (IQR) | 3% NaCl | 8 (2.75) | 8 (1.00) | 0.557* |
|                    | 0.9% NaCl | 8 (2.75) | 5.50 (3.00) | 0.542* |
| 1 week             | 6 (2.75) | 5.50 (3.00) | 0.918* |
| 2 weeks            | 4 (2.00) | 4 (3.00) | 0.304* |
| ITS; median (IQR)  | 3% NaCl | 3 (0.00) | 3 (1.00) | 0.175* |
|                    | 0.9% NaCl | 3 (0.00) | 3 (1.00) | 0.071* |
| 1 week             | 2 (1.00) | 2 (1.00) | 0.759* |
| 2 weeks            | 1 (1.00) | 1 (1.00) | 0.759* |
| PNEFR (L/min); median (IQR) | 3% NaCl | 60 (27.50) | 65 (25.00) | 0.656* |
|                    | 0.9% NaCl | 60 (20.00) | 75 (30.00) | 0.572* |

NCVAS = nasal congestion visual analog scale, IQR = interquartile range, RVAS = rhinorrhea visual analog scale, ITS = inferior turbinate size, PNEFR = peak nasal expiratory flow rate

(*) Mann Whitney U test
Discussion

Saline solution is commonly used for nasal irrigation in allergic rhinitis patients to decrease nasal symptoms and minimize over-usage of medication. The authors also encouraged that nasal saline irrigation is actually an add-on intervention according to there is not present in the ARIA standard treatment guideline. As presented in several medical studies,6,9-13 researchers have discovered an appropriate saline concentration for allergic patients; however, no definite recommendation was reported. Either isotonic saline solution, which has a composition of NaCl equal to 0.9%, or hypertonic saline solution, which consists of NaCl more than 0.9%, are widely accepted for irrigation. The hypertonic solution is prepared in several concentration of NaCl from 1.25 to 3%.9,11,13 Prior studies identified the satisfactory results in different hypertonic solutions compared to isotonic saline, including 1.25% NaCl buffered with baking soda,11 1.8% NaCl,13 2.7% NaCl,10 and 3% NaCl.9 However, higher concentrations than 3% of NaCl were not recommended.15 The study of 5.4% NaCl showed that hypertonic saline leads to substance P release and glandular secretion, stimulates nociceptive nerves and induces pain, rhinorrhea and nasal obstruction.19 On the other hand, some studies didn’t show different outcomes when the nose was irrigated by hypertonic or isotonic saline.20,21 In 2003, prospective, randomized, investigator-blinded study showed both hypertonic and isotonic solution decreased rhinorrhea however, only hypertonic solution improved nasal congestion.22 This study also showed similar results between hypertonic and isotonic solution as an evidenced by decreased rhinorrhea in both groups without any significant difference. In contrast, either hypertonic or isotonic solution can minimized nasal congestion in this study. In addition, further reason that made this study's result didn’t show any different of add-on treatment with hypertonic and isotonic nasal irrigation might be from; an approximated 70% of the patients were presented with intermittent allergic rhinitis and they were prescribed oral antihistamine which was acknowledged as an effective treatment for intermittent symptoms. Nevertheless, first week results also ensured that hypertonic saline had slight benefits to relieve nasal obstruction earlier than isotonic solution when measured by objective assessment method resulting in PNEFR.

A methodology of allergic rhinitis treatment outcome assessment is also important. Although objective measurement gives more reliability, subjective testing is also extensively used. Total nasal symptom score (TNSS) was utilized in prior studies to assess the treatment outcome.10,11,13 The main objective of this study was the effect of saline irrigation on nasal congestion and rhinorrhea; therefore, NCVAS and RVAS were chosen to be evaluated parameters. Furthermore, a precise score from 0 to 10 provided an accurate outcome.24,25 A disadvantage of subjective assessment was reported, especially in pediatric patients, because it depends on assessor experience.26 Rhinomanometry is the gold standard to objectively assess.27,28 However, it is expensive and has a complicated technique.27,28 Further equipment, such as peak nasal inspiratory flow meter29-30 and peak flow meter with anesthetic mask30-32 were adjusted for more practical usages. This study preferred peak flow meter with anesthetic mask as an assessment tool because of an availability in primary and secondary care hospital and utilization for evaluating nasal obstruction. This device provided PNEFR results, which were used to compare the nasal expiratory flow rate before and after allergic rhinitis treatment, similar to the prior studies that measured peak expiratory flow rate in allergic rhinitis patients.30-32 Additionally, this study had one more precise subjective assessment method, ITS scoring performed by flexible nasal endoscope, that reflected the degree of nasal congestion. Camacho et al14 developed grading of ITS and classified them as total airway space with grade I (0-25% of total airway space), grade II (26-50% of total airway space), grade III (51-75% of total airway space), and grade IV (76-100% of total airway space) by anterior rhinoscopy technique. This study modified their grading to scoring as 1 to 4 points, respectively. Flexible nasal endoscopy was used to assess the total airway space because this procedure provided more detail of the Cottles area,33 entire nasal cavity, and accuracy of nasal information. In their study, Abou-Elhamd KE et al14 mentioned an advantage of flexible endoscopy in identified obstruction area at posterior end of inferior turbinate. van Spronsen et al reported in 200834 that nasal endoscopy is subjective in nature; however, standardized scoring methods performed by physicians using validated scales are an objective measurement. Krouse et al35 also agree that nasal endoscopy was an objective assessment method that cannot be achieved by conventional anterior rhinoscopy.

Adverse effects from nasal irrigation using any concentration of saline solution were minimal, as reported previously, and included irritation, nasal discomfort, otalgia, and pooling of saline in sinus cavity.9,11,13,15 Mild side effects always present with short duration and spontaneous recovery within a few days10 to two weeks11,12 after starting the irrigation. Furthermore, no serious adverse reaction which interrupted nasal irrigation procedure was detected.9,11,13,15 This study finding also agreed with reports of transient adverse reactions. Only 5% of the hypertonic group reported mild nasal discomfort on the first day of the procedure. On the other hand, adverse effects were more common (10-20% of cases) when very high-volume devices (more than 100 ml/time) were used.35 Saline volume of 20 ml/time was preferred in this study, and nasal adaptors were also applied to syringes to create more suitable irrigation devices. The majority of patients in this study tolerated irrigation procedures well.

The limitations of this study included 1) small population enrollment, 2) short duration of follow-up and 3) peak flow meter with anesthetic mask is not a gold standard device for assess the nasal patency. However, the study highlights were assessment methods. Subjective assessment by VAS offered ease of response, more precise scaling, and specific to each nasal symptom, while ITS with flexible nasal endoscopy also provided more precise detail than conventional anterior rhinoscopy. And objective evaluation by PNEFR with peak flow meter and anesthetic mask also identified the alteration of nasal symptoms after nasal irrigation.
Conclusion
Both hypertonic saline or normal saline as add-on treatments have a significant improvement of all 4 parameters assessed in the study: nasal congestion, rhinorrhea, inferior turbinate size and PNEFR. Of note, 3% NaCl but not 0.9% NaCl had improved the PNEFR (L/min) earlier from 1 week of the treatment. A 20-ml syringe with nasal adaptor appliance was preferred as an irrigation device with good compliance. Finally, this study of objective assessment equipment is more practical for primary and secondary health-care settings.

Acknowledgement
The authors would like to thank Mrs. Kulchaleelak Soongsak, R.N. (otolaryngology unit, Phayao hospital) for assistance with blinding process and training the patient for nasal irrigation technique, and Mrs. Sirima Wilalak, M.Pharm (pharmacy unit, Phayao hospital) for assistance with preparing the saline solution.

Conflict of interest
The author has no conflict of interest in the past 3 years.

Author contribution
• Kedsaraporn yata: responsible for conception, design of this work, assessment/collect/interpretation the data, data analysis, writing the first draft of manuscript, approve the submitted version and any substantially modified version.
• Chonticha srivanitchapoom: responsible for data analysis, critic and edit the submitted version.

References
1. Weber RW. Allergic rhinitis. Prim Care. 2008;35:1–10.
2. Bunnag C, Jareoncharsri P, Tantilipidorn P, Vichyanond P, Pawankar R. Epidemiology and current status of allergic rhinitis and asthma in Thailand. Asian Pac J Allergy Immunol. 2009;27:79–86.
3. Uthaisangsook S. Prevalence of asthma, rhinitis, and eczema in the university population of Phitsanulok, Thailand. Asian Pac J Allergy Immunol. 2007;25:127–32.
4. Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trial. Allergy Clin Immunol. 1994;93:413–23.
5. Brožek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017:140:950-8.
6. Fregas GD, Newman NJ. Anterior Ischemic Optic Neuropathy Following the Use of a Nasal Decongestant. Am J Ophthalmol. 1999;127:104-6.
7. Lacourreye O, Werner A, Giroud JP, Coulouger V, Bonfils P, Bondon RS, Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Arch Otorhinolaryngol. 2015:132:31-4.
8. Mortuine G, de Gabory L, François M, Massé G,Bloch F, Brion N, et al. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Arch Otorhinolaryngol Head Neck Dis. 2013;130:137–44.
9. Ural A, Oktener TK, Kusul Y, Ilker F, Uslu S. Impact of isotonic and hypertonic saline solutions on mucociliary activity in various nasal pathologies: clinical study. J Laryngol Otol. 2009;123:517–21.
10. Marchisio P, Varricchio A, Baggi E, Bianchini S, Capasso ME, Torretta S, et al. Hypertonic saline is more effective than normal saline in seasonal allergic rhinitis in children. Inter J Immunopath Pharmacol. 2012;25:721-30.
11. Salthabudha A, Poachanukoon O. Efficacy of buffered hypertonic saline nasal irrigation in children with symptomatic allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2012;76:583-8.
12. Hermelömgmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy. 2012;26:119-25.
13. Sansila K, Eiamprapai P, Sawangjit R. Effects of self-prepared hypertonic nasal saline irrigation in allergic rhinitis: a randomized controlled trial. Asian Pac J Allergy Immunol. 2018;Dec 9. doi:10.12932/AP-090618-0331. [Epub ahead of print].
14. Kahanawasee D, Sereisirikachorn K, Chitsuthipakorn W, Snivongs K. Hypertonic saline versus isotonic saline nasal irrigation: systematic review and meta-analysis. Am J Rhinol Allergy. 2018;32:269-79.
15. Principi N, Esposito S. Nasal Irrigation: an imprecisely defined medical procedure. Int J Environ Res Public Health. 2017;14.
16. Elkins MR, Bye PT. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011;104:2-5.
17. Li HB, Shi JB, Cao F, Cheng L, Wen WP, Xu G. Hypertonic saline solution stimulated CLC-3 production in primary cultured human nasal epithelial cells. Auris Nasus Larynx. 2008;35:47–51.
18. Camacho M, Zaghi S, Cerral V, Abdulatif J, Means C, Acevedo J, et al. Turbinate classification system, grades 1 to 4: development and validation study. Laryngoscope. 2015:125:296-302.
19. Baranik JN, Ali M, Yuta A, Fang SY, Naranch K. Hypertonic saline nasal provocation stimulates nociceptive nerves, substance P release, and glandular mucous exocytosis in normal humans. Am J Respir Crit Care Med. 1999;160:655–62.
20. Sakakura Y, Ukae M, Majima Y, Murai S, Harada T, Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol. 1983;96:167–73.
21. Sakakura Y, Majima Y, Saida S, Ukae K, Miyoshi Y. Reversibility of reduced mucociliary clearance in chronic sinusitis. Clin Otolaryngol. 1985;10:79–83.
22. Talbot AR, Herr TM, Parsons DS. Mucociliary clearance and buffered hypertonic saline solution. Laryngoscope. 1997;107:500–3.
23. Garavello W, Romagnoli M, Sordi L, Gaini RM, Di Berardino C, Angrisano A. Hypersaline nasal irrigation in children with symptomatic allergic rhinitis: a randomized study. Pediatr Allergy Immunol. 2003;14:140–3.
24. van Sproosn E, Ingels KJ, Janssen AH, Graamans K, Fokkens WJ. Evidence-based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new grade system. Allergy. 2008;63:820–33.
25. Camacho M, Zaghi S, Cerral V, Abdulatif J, Modiri R, Srithara S, et al. Predictors of nasal obstruction: quantification and assessment using multiple grading scales. Plast Surg Int. 2016;2016:6945297.
26. Jeffe JS, Bhushan B, Schroeder JW Jr. Nasal saline irrigation in children: a study of compliance and tolerance. Int J Pediatr Otorhinolaryngol. 2012;76:409–13.
27. Vogt K, Bachmann-Harildstad G, Lintemann A, Nechyporenko A, Peters F, Wennecke KD. The new agreement of the international RIGA consensus conference on nasal airway function tests. Rhinology. 2018;56:133-43.
28. Holmstrom M, Scadding GK, Lund VJ, Darby YC. Assessment of nasal obstruction. A comparison between rhinomanometry and nasal inspiratory flow peak. Rhinology. 1990:281:191-6.
29. de Souza Campos Fernandes S, Ribeiro de Andrade C, da Cunha Ibiapina C. Application of Peak Nasal Inspiratory Flow reference values in the treatment of allergic rhinitis. Rhinology. 2014;52:133-6.
30. Blomgren K, Simola M, Hytönen M, Pitkäranta A. Peak nasal inspiratory and expiratory flow measurements - practical tools in primary care? Rhinology. 2003:41:206-10.
31. Taylor G, Macneil AR, Freed DL. Assessing degree of nasal patency by measuring peak expiratory flow rate through the nose. J Allergy Clin Immunol. 1973;52:193-8.
32. Ellegard EK, Ellegard LH. Nasal peak expiratory flow and nasal congestion in women: how many subjects are enough? Therapy. 2006;3:89-92.
33. Zambetti G, Filiaci F, Romeo R, Soldo P, Filiaci F. Assessment of Cottle's areas through the application of a mathematical model deriving from acoustic rhinometry and rhinomanometric data. Clin Otolaryngol. 2005;30:128-34.
34. Abou-Elhamd KE, Sayed RH. Assessment of nasal obstruction with flexible nasal endoscopy, Saudi Med J. 2006;27:1850-2.
35. Krouse J, Lund V, Fokkens W, Meltzer EO. Diagnostic strategies in nasal congestion. Int J Gen Med. 2010;3:59-67.